United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin® | United Therapeutics CorporationPublished on :
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity ® Pump for Remodulin ® for patients with pulmonary arterial hypertension (PAH). “We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients,” said Beth Rhodes, Vice President, Global Supply Chain Alliance Management…
The combination of a booming biotech market with an additional surge of hiring by vaccine and diagnostic companies in Maryland has resulted in record-low unemployment and competition for talent at an all-time high.
Former MedImmune Employees Leading In the BioHealth Capital Region and Beyond In a recent conversation someone shared the quote “You can’t throw a stone in the BioHealth Capital Region and [….]
United Therapeutics Headquarters in Silver Spring, MD, named Unisphere, is one of the largest net-zero commercial buildings in the US.
Image Credit: www.utunisphere.com October 1, 2018 The Unisphere Opens in Silver Spring to Grow Transplantable Organs with a Net Zero Carbon Footprint On Friday, September 21st United Therapeutics celebrated the [….]